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Abstract. There is strong evidence suggesting the presence 
of a genetic component in the aetiology of multiple myeloma 
(MM). However no genetic risk factors have been unequivocally 
established so far. To further our understanding of the genetic 
determinants of MM risk, a promising strategy is to collect a 
large set of patients in a consortium, as successfully done for 
other cancers. In this article, we review the main findings in the 
genetic susceptibility and pharmacogenetics of MM and present 
the strategy of the IMMEnSE (International Multiple Myeloma 
rESEarch) consortium in contributing to determine the role of 
genetic variation in pharmacogenetics and in MM risk.
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1. Introduction: multiple myeloma
Multiple myeloma (MM) is a malignancy of plasma cells usually 
infiltrating the bone marrow, associated with the production 
of a monoclonal immunoglobulin (M protein) which can be 
detected in the blood and/or urine (1). The uncontrolled growth 
of myeloma cells has many consequences, including skeletal 
destruction, bone marrow failure, suppression of normal 
immunoglobulin production and renal insufficiency (2).
MM arises worldwide at an age-standardized (ASR) rate of 
1.5 new cases every 100,000 people per year and is responsible 
of an ASR of mortality of 1 in 100,000 subjects per year. In 
Europe the ASR incidence is 2.9 new cases every 100,000 
people, ranging from 4.2 in Luxembourg to 0.9 in Moldova, 
and is about 1.5-fold higher in males (ASR=2.9) than in females 
(ASR=2.0) (3-5). The highest annual incidence of MM has been 
found in African Americans followed either by Europeans 
or American Caucasians and Asians who present the lowest 
incidence even when they live in Western societies (6-11). The 
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overall incidence rates range from a high of 13.1/100,000 per 
year for black males to 2.9/100,000 per year for white females 
(8,11). MM is common in the elderly, with incidence rates 
increasing with age, it occurs rarely before 40 years (12) and 
presents an extremely low frequency in young people (9,13,14). 
It has been shown that MM could evolve from an asymptom-
atic premalignant condition termed monoclonal gammopathy 
of undetermined significance (MGUS) (15,16). The frequency 
of MGUS is over 3% in the population above the age of 
50 years and over 5% in persons aged 70 years or older (17,18). 
This condition seems to be related to progression to MM or 
other plasma cell disorders at a steady rate of 1.5% per year, 
and after >25 years of observation about 15-17% of MGUS 
subjects develop MM (19). In some patients, an intermediate 
asymptomatic, but more advanced premalignant stage, defined 
as smouldering multiple myeloma (SMM) could be clinically 
recognized (20).
MM diagnosis requires 10% or more clonal plasma cells on 
bone marrow examination or a biopsy proven plasmacytoma 
and evidence of end-organ damage such as hypercalcemia, 
renal insufficiency, anaemia or bone lesions, defined as CRAB 
(calcium elevation, renal insufficiency, anaemia and bone 
lesions criteria) that can be related to the underlying plasma 
cell disorder (1,21).
Symptomatic (active) disease should be treated immediately, 
whereas asymptomatic myeloma requires only clinical obser-
vation, since early treatment with conventional chemotherapy 
has shown no benefit. The aim of the therapy is represented 
by the achievement of the best possible response: complete 
response (CR) or very good partial response (VGPR) (22-24). 
The level of response, and in particular achievement of CR, 
seems to be associated with an improved long-term outcome. 
Overall survival (OS) in myeloma has improved significantly 
in the last decade with the emergence of thalidomide (25), 
bortezomib (26) and lenalidomide (27). Bortezomib is a first-
in-class proteasome inhibitor (28); the complete mechanism 
of action of thalidomide and lenalidomide is still unclear but 
both of them are immune-modulatory drugs (29). Treatment 
strategies include the use of therapy with thalidomide, lenalid-
omide or bortezomib plus hematopoietic autologous stem-cell 
transplantation (ASCT) for patients under the age of 65 years, 
who do not have substantial heart, lung, renal or liver dysfunc-
tion. Alternatively, the use of combination therapy including 
steroids and/or alkylating agents together with one or two of 
the new drugs (thalidomide, bortezomib and lenalidomide) 
is more appropriate for elderly patients or those with severe 
co-morbidities. The role of maintaining therapy is still a 
matter of debate (30).
2. Lifestyle, environmental and occupational-related risk 
factors in multiple myeloma
MM risk is clearly related to age (31), gender, ethnicity (11) and 
the presence of pre-malignant conditions such as MGUS (17). 
Additional factors have been suggested to have an effect on 
the risk of developing MM. There is epidemiological evidence 
supporting an increased risk of MM among obese people and 
for those who have a low intake either of fish or vegetables 
(32-36). A number of cohort and case-control studies have also 
described a positive relationship between MM and patients 
either with autoimmune diseases (37,38) or viral infections 
(39-41). Many other studies have investigated the relationship 
between exposure to toxins and increased risk of MM, with 
controversial results (42-46). While some studies have shown 
that exposures to pesticides (47-49), organic solvents (50), 
hairdresser's products (51), rubber (52) are associated with an 
increased risk of MM, other studies have not found a signifi-
cant relationship (48,53-55). Researchers have also examined 
whether smoking (56), alcohol consumption (57) or ionizing 
radiation exposures (58) affected the risk of MM but, again, 
obtained data were largely inconsistent (59-61).
3. Genetic risk factors in multiple myeloma
Converging evidence of MM in monozygotic twins (62) and 
familial aggregation of MM (63-69) strongly suggest that MM 
aetiology has a robust genetic component. For many other 
types of tumors, association studies, including Genome-Wide 
Association Studies (GWAS), have shown that genetic risk is 
influenced by the effect of the co-inherited common genetic 
low-penetrance variants. Single Nucleotide Polymorphisms 
(SNPs) are the major source of genetic variation in humans 
and thought to be responsible, at least in part, for the individual 
differences in genetic susceptibility to complex diseases as 
tumors. This is likely to be the case for MM as well. Several 
genes belonging to different pathways have been associated 
with MM risk, although the results were controversial. Table I 
summarizes the positive associations reported in the literature 
between genetic variants and MM susceptibility in candidate 
gene studies. Up to date, a GWAS on MM risk is still lacking.
Polymorphisms in cytokine genes. The first study on SNPs 
in MM genetic susceptibility was reported in 2000 by Zheng 
et al and investigated the role of 3 SNPs, respectively, in 
TNF‑α (-308G/A, rs1800629), IL6 (-174G/C, rs1800795) and 
IL1B (+3954T/C, rs1143634) genes as well as a VNTR poly-
morphism in the IL1RN gene. In this study, no evidence of 
association between any of the studied genetic variants and 
MM risk was reported (70).
In general, cytokine-encoding genes have been extensively 
investigated (70-86), due to the high degree of polymorphisms 
characterized in these genes and to their important role in the 
bone marrow microenvironment and B-cell development.
One of the most investigated genetic loci in MM risk is the 
-308G/A SNP (rs1800629) which belongs to the TNF‑α gene. 
While no association between MM risk and SNP -308G/A 
(rs1800629) of TNF‑α gene was found in a previous study (70), 
Davies and colleagues showed a significantly higher percentage 
of heterozygous individuals for both TNF‑α -308G/A SNP and 
LT‑α +252A/G (rs909253) SNP among MM cases in respect 
to controls, suggesting that the higher TNF‑α producers had a 
2-fold higher risk to develop MM (78). In a subsequent study, 
Morgan et al failed to confirm the association between TNF‑α 
-308G/A and LT‑α +252A/G haplotype and MM risk, evidencing 
on the other hand an association between the TNF‑α -308A 
allele and a decreased risk to develop MM (79). The association 
of the TNF‑α -308A allele with a reduced risk to develop MM 
has been confirmed by two recent studies (73,83).
Investigations of SNPs in genes belonging to the IL6 path way 
are intriguing since IL6 and IL6-mediated signaling are thought 
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to be relevant players in MM pathogenesis (87). Several reports 
investigated SNPs in IL6, IL6R and IL6ST genes (75,76,80-82) 
and up to date, several studies failed to evidence association 
with the well studied IL6 promoter -174G/C SNP (rs1800795) 
(70,75,80-82). In one study the IL6 -572G/C (rs1800796) was 
associated with an increased risk to develop MM for carriers 
of the -572C allele (75). However, this association was not 
confirmed in a following study (82), whereas an increased 
risk of MM was found for carriers of the minor allele of SNPs 
D398A (rs8192284), rs7529229 and rs6684439 in the IL6R 
gene. Nevertheless, association within IL6R SNP rs8192284 
was investigated in a third study that did not confirm the 
previous findings (81). Several SNPs in other cytokines and 
immunity-related genes, such as IL1B, IL1A, IL1RN (77,85), 
IL4R and FCGR2A (86) have been found to be associated 
with MM risk, although there is a lack of replication studies 
limiting the applicability of these findings.
Polymorphisms in growth factors and cell signaling genes. The 
complex network of signaling pathways activated by several 
proteins present in the bone marrow microenvironment play a 
relevant role in malignant plasma cells proliferation, migration 
and survival (88). The activation of the nuclear transcription 
factor NF‑κB is thought to be one of the most important factors 
to enhance cell proliferation in MM pathogenesis (89,90). The 
minor alleles of SNPs in genes related to the NF‑κB pathway, 
such as the inhibitor IκBα (rs2233406, rs3138054, rs2233419) 
and the transcriptional activator TRAF3 (rs12147254) have been 
associated with a protective effect on MM development (91-93).
Several polymorphisms in genes related to insulin meta-
bolism resulted associated with MM risk. In particular, three 
SNPs in the IGF1 gene (rs7965399, rs2195239, rs2373722), one 
in the IGFBP3 (rs3110697) gene and two in the IRS1 gene have 
been associated both with increased or decreased risk of MM 
(82).
Several SNPs in other immunity-related and adhesion/
growth genes, such as SERPINE I, CCR7, HGF, JAK3 (94), 
CD4 (71), RIPK1 (95) and HPSE (96) have been found to be 
associated with MM risk. Nevertheless, these results wait to 
be replicated in independent populations. Other reports did not 
evidence significant results (97).
Polymorphisms in DNA repair, cell cycle and apoptosis genes. 
SNPs in genes of the DNA repair system have been deeply 
investigated to uncover the genetic susceptibility of many cancer 
types, including MM (98-100). The observation of recurring 
translocation in MM patients involving the 14q32.3 cytogenetic 
band, which is considered the primary genetic event leading to 
the malignant transformation of the plasma cells, has supported 
the idea that alteration of the class switch recombination (CSR) 
process could play a fundamental role in MM pathogenesis. The 
XRCC5 gene encodes for the Ku80 protein, that together with 
Ku70 (XRCC6) constitutes the Ku70/Ku80 complex that acts 
in the recognition of double strand breaks (DSBs). The DNA 
breakpoints recognized by Ku70/Ku80 are subsequently joined 
by the XRCC4/DNA ligase IV complex. Interestingly, some 
authors reported associations of XRCC4 (rs963248), XRCC5 
(rs1051685) and LIG4 A3V (rs1805389), T9I (rs1805388) SNPs 
with MM susceptibility (98,99). In particular, carriers of the 
XRCC4 rs963248 G allele as well as carriers of the XRCC5 
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rs1051685 G allele showed an increased risk to develop MM 
(98), while heterozygotes for the LIG4 A3V SNP as well as 
rare homozygotes for the LIG4 T9I SNP have been shown to 
have a lower susceptibility to MM (99). SNPs in BAX, CASP3 
and CASP9 genes were found to be associated with MM risk 
in women (95,101), while the p53 codon 72 polymorphism 
(102) and SNPs in XRCC3 and ERCC2 genes (98,100) showed 
no associations with MM risk.
Polymorphisms in xenobiotic metabolism and transport genes. 
SNPs in genes codifying for enzymes acting in phase I, phase II 
metabolic reactions and phase 0/III transport have been also 
investigated for associations with genetic susceptibility to MM. 
Glutathione-S-transferases (GSTs) conjugate phase I activated 
metabolites to favour their excretion from the organism. 
Polymorphisms in the GSTM1, GSTT1 and GSTP1 loci have 
been investigated in several case-control studies with weak 
evidence of association (102-105). Although not confirmed in 
other studies, Lincz et al showed an association between the 
GSTT1 null genotype and an increased MM risk. The authors 
also showed an association of both the rare homozygotes for the 
Q192R (rs662) SNP in the PON‑1 genes and NAT2 rapid/slow 
phenotype with an increased risk of MM (105). In a following 
study on polymorphisms in genes involved in benzene metabo-
lism Lincz et al evidenced an increased susceptibility to MM 
for carriers of ‘high-risk genotypes/phenotypes’ of GSTT1 
(null), NQO1 (187PS/SS, rs1800566) and mEH (high activity) 
genes as well as for the G/G homozygotes for the mEH H139R 
(rs2234922) polymorphism (106). Nevertheless, in another 
study investigating NQO1 P187S (rs1800566), PON‑1 Q192R 
(rs622) and mEH H139R (rs2234922) SNPs no associations 
were found (107).
Folate-metabolizing enzymes have been also intensely 
investigated in relation to MM risk. MTHFR, which has been 
found associated with cancer risk (108,109), is one of the 
most important enzymes involved in the regulation of folate 
homeostasis. Two MTHFR missense SNPs, C677T (rs1801133) 
and A1298C (rs1801131), were investigated in relation to MM 
susceptibility in various reports with evidence for association 
(110-112) as well as for no association (113-117). Recently, a 
meta-analysis confirmed a possible role for the MTHFR C677T 
(rs1801133) SNP in MM susceptibility, with an increased risk 
for carriers of the 677T allele (118). The minor allele (G) of 
the missense substitution A2756G (rs1805057) in the enzyme 
methionine syntase (MS or MTR) has been found associated 
with higher risk of MM in a mixed Caucasian and African-
American population (112), but with decreased risk in an 
Asian population (114). However, this effect was not observed 
in a third study (117). SNPs in other genes such as ABCB1, 
TYMS, CYP1A1 and CYP1B1 have been also investigated 
and showed modest evidence of association with MM risk 
(107,112,114,119,120).
4. Pharmacogenetics of multiple myeloma
The study of pharmacogenetics in MM is relatively recent, the 
earliest studies dating back to early 2000. Several studies have 
explored factors influencing the individual response to chemo-
therapies and the resulting survival, while other studies have 
tried to further our understanding on adverse reaction to drugs.
Role of SNPs in therapy outcome and survival. Associations 
between several genetic variants and therapy outcome have 
been already reported. The TNF‑α promoter SNP -238G/A 
(rs361525) has been associated with response to a thalido-
mide maintenance therapy in relapsed and refractory MM, 
showing a prolonged progression-free survival (PFS) and 
OS for carriers of the A allele (121). Interestingly, borderline 
association of TNF‑α gene polymorphisms and PFS has been 
observed in previous studies (78,79) and a significant associ-
ation of the TNF‑α -238A allele with a better PFS and OS in 
patients treated with thalidomide and dexamethasone has been 
confirmed by recent findings (73).
Dasgupta et al showed association of the I105V (rs1695) 
SNP of the GSTP1 gene with a better PFS in MM patients 
homozygous for the 105V allele after standard and high-dose 
chemotherapy (HDM) (122). A similar association between 
105V homozygotes for the GSTP1 SNP I105V (rs1695) and 
MM outcome after DAV (dexamethasone/adriamycin/vincris-
tine) induction therapy has also been described by others 
(123,124).
Homozygotes for the T allele of TYMS +157C/T (rs699517) 
polymorphism have been shown to have a worse response to 
ASCT (124). An association with an improved outcome after 
HDM and ASCT in MM patients and a near-to-significance 
association with an improved OS for the T allele for the SNP 
rs1051296 in the folate transporters SLC19A1 gene has also 
been reported (125).
Due to their importance in the determination of drug 
bioavailability, drug metabolizing enzymes and drug trans-
porters coding genes are among the most investigated for a 
role in MM pharmacogenetics. Among these, ABCB1 has been 
widely studied. In particular the well known ABCB1 C3435T 
(rs1045642) and G2677A/T (rs2032582) polymorphisms were 
found associated with outcome of different treatments in MM 
patients (123,126-128). The T allele of the ABCB1 C3435T has 
been associated with a better response to DAV treatment (123), 
a better response and a better PFS (T/T homozygotes) after 
bortezomib treatment of relapsed and/or refractory myeloma 
patients (128,129) and with better OS of MM patients (130). 
The rare T allele of the triallelic ABCB1 SNP G2677T/A has 
been associated to a better response to DAV (123) and a better 
OS (127) in MM patients.
SNPs in genes encoding drug metabolizing enzymes 
belonging to the cytochrome P450 family have been investigated 
as well (i.e., CYP2C19, CYP2D6, CYP3A4) with controversial 
results (123,126,131,132). In a study investigating two polymor-
phisms of CYP2C19 gene, poor metabolizer phenotype was 
associated with a poor response to thalidomide-based therapies 
(132). Vangsted et al showed the association of ERCC2 K751Q 
(rs1052559), XRCC3 T241M (rs861535), CD3EAP -21G/A 
(rs967591) (100) and IL1B -31T/C (rs1143627) (85) polymor-
phisms with outcome after ASCT in MM patients receiving 
HDM. In particular, carriers of the ERCC2 K751Q C allele, the 
variant T allele of XRCC3 T241M and the A allele of CD3EAP 
21G/A SNP had a better time to treatment failure (TTF) in 
respect to homozygous wild-type carriers and the variant A 
allele of CD3EAP 21G/A resulted also associated with a better 
OS (100). Carriers of the variant C allele for the IL1B -31T/C 
SNP showed a significantly improved OS than T carriers (85). 
A role of the NFKB1 -94 ins/delATTG polymorphism has been 
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shown in patients receiving Interferon-α (IFN-α) as mainte-
nance therapy after HDM (133). Interestingly, in a recent study, 
Vangsted et al investigated additional genetic variants in the 
IL1B promoter region and their impact on TTF, OS and IFN-α 
maintenance therapy. Carriers of the T allele of the IL1B 
C-3737T (rs4848306) as well as carriers of the TGT haplotype 
resulting from the IL1B SNPs C-3737T, G-1464C (rs1143623) 
and T-31C (rs1143627) showed a reduced OS and TTF. In 
addition, carriers of the combination IL1B-3737T allele/
NFKB1 -94 delATTG alleles showed a better TTF and OS in 
patients treated with a IFN-α maintenance therapy (134). An 
association between the carriers of the G allele for the -8C/G 
SNP in the 20S proteasome subunit coding gene PSMA6 and 
a better 5-year OS has been also shown (135). Recently, Du 
et al evidenced the association of the carriers of the A allele 
of the TRAF3 SNP rs11160707 with an improved PFS, while 
the variant alleles for two NFKB2 SNPs (rs12769316 and 
rs1056890) were associated, respectively, with an increased 
and a decreased OS (93).
Role of SNPs in treatment‑related side effects and toxicity. 
Treatment-related neuropathy is one of the most common 
side effects in MM and affects about 40-64% of the patients 
treated with bortezomib (136). Peripheral neuropathy has been 
registered also following thalidomide treatment in about 40% 
of the patients (137) and, at a minor grade, in patients treated 
with lenalidomide (138). Recently, Broyl et al showed several 
SNPs in different genes to be related with early- and late-
onset bortezomib induced neuropathy. In particular, SNPs in 
CASP9 (rs4646091), RDM1 (rs2251660), ALOX12 (rs1126667, 
rs434473), LSM1 (rs7823144), IGFR1 (rs1879612) and NEK4 
(rs1029871) genes associated with early-onset bortezomib 
induced neuropathy, while SNPs in ERCC4 (rs1799800, 
rs1799801), SRD5A2 (rs2300697), IFNGR2 (rs1059293), 
ERCC3 (rs2276583), ATM (rs189037, rs664677, rs664982), 
MRE11A (rs10501815), SELP (rs6131), PTPRN2 (rs1130499), 
STK31 (rs4722266) and PPARD (rs2267668) genes associ-
ated with late-onset bortezomib induced neuropathy (139). 
Several authors investigated the role of genetic variation in 
thalidomide-related adverse effects. Johnson et al analyzed a 
panel of over 3,400 SNPs in 964 genes in 1,495 patients from 
different clinical trials, showing overall associations of SNPs 
in SERPINE1 (rs7242), ADRB2 (rs2082382, rs1042714), ID3 
(rs1555026), CYP2C9 (rs1934951), CAMKK1 (rs7214723), 
CYP2C8 (rs1058932), SLC10A2 (rs2301157) and NFATC2 
(rs228832) genes with thalidomide-related neuropathy (140). 
The same SNP panel has been used to investigate the role 
of genetic variation in the occurrence of thalidomide-related 
venous thrombotic events (VTEs). The results showed a total 
of 18 SNPs, validated in 2 patient groups from different clinical 
trials, associated with the occurrence of VTEs in thalidomide 
treated patients (141). The use of bisphosphonates in MM 
could be associated with the development of osteonecrosis of 
the jaw (ONJ) (142) and Sarasquete et al showed a statistically 
significant association of the CYP2C8 SNP rs1934951 with the 
occurrence of ONJ (143).
5. Limits and perspectives: the rationale for the IMMEnSE 
consortium
Despite several efforts towards the comprehension of the role 
of common genetic variability in modifying the individual 
risk to develop MM, to date no locus has been unequivo-
cally established as risk factor for MM development. The 
fairly small sample sizes (ranging from 26 to 352 cases) of 
the published studies, due in part to the low incidence of the 
disease, could represent one fundamental limiting factor to 
detect genetic associations with MM risk. This is particularly 
important considering the fact that the genetic risk to develop 
MM is likely influenced by low-penetrance variants the 
Table II. The IMMEnSE consortium participating centres.
Centres Country
Hospital and Clinical Centres
Department of Oncology, Transplants and Advanced Technologies, Section of Haematology, Pisa, Italy
Pisa University Hospital
Department of Hematology, Medical University of Lodz Lodz, Poland
Division of Hematology, University Hospital of Salamanca Salamanca, Spain
Department of Hematology and Hemotherapy, University Hospital Virgen de las Nieves Granada, Spain
Hospices Civils de Lyon Lyon, France
Hospital de Braga Braga, Portugal
IDIBELL-Catalan Institute of Oncology and University of Barcelona Barcelona, Spain
Research institutions
Genomic Epidemiology Group, DKFZ (German Cancer Research Center) Heidelberg, Germany
Genomic Oncology Area, GENYO (Pfizer-University of Granada-Andalusian Government Centre Granada, Spain
for Genomics and Oncological Research)
Division of Genetics, Department of Biology, University of Pisa Pisa, Italy
International Agency for Research on Cancer IARC, Genetic Cancer Susceptibility Group Lyon, France
Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho Braga, Portugal
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effect of which is difficult to detect in uncommon diseases. 
Moreover, this limit can explain, at least in part, the failure 
of the replication effort suffered by several studies so far 
reported. Even if meta-analyses can overcome the size limits 
that occur in single studies, limited data exist to date. One 
viable option to further our understanding in the genetic 
determinants of MM risk is to unify a large set of patients 
across different populations and cohorts in a consortium. This 
strategy has been shown to be successful for various cancer 
sites, as shown on one hand by several GWAS in which several 
new risk loci were discovered (144,145) and on the other hand 
by various candidate gene studies nested in large cohorts 
used to replicate or disproof known findings (146). This effort 
is of the uttermost importance for a low-prevalence disease 
such as MM. Moreover, a large collection of samples possibly 
joined by a meticulous collection of co-variates of clinical 
importance, not only provides a greater advantage in terms 
of power for risk study, but allows also a more exhaustive 
investigation of pharmacogenetics. Given the heterogeneity 
of the treatments in the patient populations, the possibility to 
unite several sets of patients allows the individuation of larger 
subgroups receiving similar therapies.
The IMMEnSE consortium. The International Multiple 
Myeloma rESEarch (IMMEnSE) consortium aims to 
improve the understanding of genetics and pharmacogenetics 
of MM. The driving idea of the IMMEnSE consortium is 
to join together the efforts of different research groups with 
the constitution of a large bio- and databank to allow more 
powerful and meaningful investigations able to uncover 
the role played by genetic variants in MM genetics, as 
successfully done for other diseases (147,148). To date, the 
IMMEnSE consortium brings together twelve basic and/or 
clinical research groups with a wide spectrum of expertise 
and spreads widely across six European countries (Table II). 
Recognizing the need for further expansion of this network, 
the recruiting of collaborators and partner institutions is 
continuously ongoing.
The cases included in the consortium population are 
defined by a confirmed diagnosis of MM, according to the 
International Myeloma Working Group (IMWG) criteria (1). 
For each patient, information about gender, age at diagnosis, 
β2-microglobulin, albumin, creatinin, haemoglobin, bone 
lesions and previous clinical history at diagnosis are collected. 
Detailed information concerning front line and relapsed/
refractory patients therapies are collected, as well as the 
individual response to them. PFS from ASCT, OS and toxicity 
events are registered as well to investigate the role of genetic 
variants in the pharmacogenetics of MM. Moreover, with the 
aim to investigate genetic variables involved in the transition 
from MGUS to MM, positive history of MGUS is registered. 
So far, 743 MM cases diagnosed between 1992 and 2010 have 
been retrospectively recruited in each participating centre up 
to now and collected at the German Cancer Research Center, 
where the DNA bank and the central database have been set up. 
The collection of MM and MGUS cases is currently ongoing 
in every participating centre and the population is expected to 
reach 2000 cases within 3 years.
Different region-specific subpopulations of unmatched 
controls have been selected for a total of 950 healthy individuals 
enrolled to date. Controls have been selected among the general 
population as well as among hospitalized subjects with different 
diagnosis excluding cancer. Gender and age at recruitment are 
collected for every subject enrolled. For each subject, informed 
consent to collect fresh blood and perform DNA extraction for 
research purpose has been requested and collected individu-
ally by each centre. Genetic analyses are being performed in 
the German Cancer Research Center (Heidelberg, Germany). 
Detailed information on the demographic and clinical charac-
teristics of the IMMEnSE consortium population are described 
in Table III.
6. Future directions
Epidemiological studies have been shown to be of great value 
to the understanding of the biology of many other cancer types. 
The available results on genetic risk of MM clearly evidence 
the necessity of additional studies assessing also the interplay 
of genetic and clinical factors to fully understand the molecular 
mechanisms underlying the susceptibility to MM. At the same 
time, the consortium aims to contribute to the understanding 
Figure 1. Statistical power of genetic association studies on MM (α=0.05). This 
figure describes the minimum OR detectable with a power of 80% and a MAF 
from 0.05 to 0.5 with a type I error α=0.05, depending on the sample size. 
The minimum OR detectable decreases considerably with larger sample sizes. 
The IMMEnSE population ensures the statistical power to detect possible 
associations between low-penetrance genetic variants and MM risk.
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of how the genotype may predict the clinical outcome and the 
degree of response to treatments, in order to offer new clues 
to optimize treatment and to improve patients' lives. Thus, the 
IMMEnSE consortium will also allow the optimization of the 
efforts towards the translational implementation of genetic 
findings.
Replication of best associated SNPs. In the proposed frame-
work of the IMMEnSE consortium, the first objective is to 
conduct a comprehensive replication of the most important 
and significant genetic associations found with MM risk. As 
shown in Fig. 1, the current size of the IMMEnSE population 
is already enough to guarantee a statistical power over 80% 
Table III-A. Demographic and clinical characteristics of MM cases.
 Cases ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Characteristics 1a 2a 3a 4a 5a 6a Alla
Age at diagnosis (years)
 Mean (±SD) 62.53 (±9.93) 61.85 (±10.41) 62.88 (±11.75) 64.25 (±9.90) 55.96 (±9.31) 66.78 (±10.49) 61.34 (±10.38)
 Median (range) 63 (35-87) 62 (39-86) 62 (31-93) 64 (39-86) 58 (27-75) 68 (43-86) 62 (27-93)
Gender N (%)
 Male 122 (52.3) 71 (49.3) 67 (52.3) 39 (42.8) 52 (56.5) 26 (47.3) 377 (50.7)
 Female 111 (47.7) 73 (50.7) 61 (47.7) 52 (57.2) 40 (43.5) 29 (52.7) 366 (49.3)
 Total 233 (31.4) 144 (19.4) 128 (17.2) 91 (12.2) 92 (12.4) 55 (7.4) 743 (100)
Ascertainment period 1992-2009 1993-2009 1990-2009 1991-2006 1995-2005 2007-2010 1990-2010
Stage at diagnosis (%)
 Durie-Salmon 15.1/21.4/63.5/48.3
 I/II/III/ND
 ISS 52.9/23.0/24.1/76.6
 I/II/III/ND 
Prognostic markers
 β2-microglobulin (µg/l) 3.39 (1.99-5.90)b
 Creatinin (mg/dl) 1.0 (0.8-1.3)b
 Albumin (g/dl) 3.9 (3.5-14.6)b
 Haemoglobin (mg/dl) 10.8 (8.8-12.7)b
B, Demographic characteristics of controls by population.
 Controls -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Characteristics Italian Polish Spanish French Portuguese All
Age at diagnosis
(years)
 Mean (±SD) 58.81 (±10.95) 69.50 (±6.67) 65.21 (±13.45) 53.12 (±6.28) 60.68 (±7.72) 57.11 (16.09)
 Median (range) 59 (35-89) 69 (55-98) 66 (24-92) 51.5 (41-68) 58 (51-85) 59 (18-98)
Gender N (%)
 Male 131 (52.3) 69 (49.3) 173 (52.3) 68 (52.5) 55 (56.5) 476 (52.1)
 Female 106 (47.7) 81 (50.7) 158 (47.7) 64 (48.5) 45 (43.5) 437 (47.9)
 Total 237 (25.0) 150 (15.8) 331 (34.8) 132 (13.9) 100 (10.5) 950
Control type General Blood Hospitalized Blood Blood
  population donors  donors donors
a1, Department of Oncology, Transplants and Advanced Technologies, Section of Haematology, Pisa University Hospital, Pisa, Italy; 2, Department 
of Hematology, Medical University of Lodz, Lodz, Poland; 3, Division of Hematology, University Hospital of Salamanca, Salamanca, Spain; 4, 
Department of Hematology and Hemotherapy, University Hospital Virgen de las Nieves, Granada, Spain; 5, Hospices Civils de Lyon, Lyon, France; 
6, Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal. bMedian (25th-75th). 
ND, no data.
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for the identification of an OR of 1.5 with a Minor Allele 
Frequency (MAF) of 0.05, up to an OR of 1.25 with a MAF 
of 0.25 or greater. Besides, taking into account the ongoing 
recruitment of MM cases, this power is destined to grow. Thus, 
these results should make a significant improvement to the 
interpretation of the controversial results published to date.
GWAS, validation of associated loci and rare SNP analysis. 
The contribution of GWAS in the identification of new loci 
associated with risk of several cancer types has been of 
extreme importance in the last few years. Up to date, no 
GWAS has been conducted on MM. As soon as GWAS data 
will be available also for MM risk, the IMMEnSE population 
will constitute a valuable tool for replication and confirmation 
of the most interesting results. Moreover, given that GWAS 
studies still lack the coverage of less common variants (i.e., 
MAF <5%), their investigation in candidate-gene approach 
studies will still be of primary importance in MM genetic risk 
assessment. In this context, the aim of the IMMEnSE consor-
tium will be to investigate genetic variants in regions shown to 
be possible actors in the pathogenesis of MM.
Identification of tagged functional variants. Tagging SNPs 
are unlikely to be directly responsible for the effect seen on 
disease risk. The identification of functional genetic variants 
associated with tag SNPs is one of the most fascinating and 
important challenges in the near future. While tag SNPs can 
sufficiently cover linkage disequilibrium (LD) blocks within 
a region, direct sequencing or fine mapping of the associated 
loci are often needed to determine the effective genetic variants 
able to impact the MM risk. Availability of samples from 
MM cases will be paramount for these tasks, both to perform 
sequencing of targeted regions in order to discover potentially 
causal variants and/or to test whether such candidate vari-
ants show a stronger association than tag SNPs identified by 
GWAS.
Multifactorial risk scores. The impact of common low-
penetrance variants taken individually is expected to be very 
small. Nevertheless, the interactions of many modest contri-
butions could lead to a significant improvement of MM risk. 
The cumulative risk could be determined from interactions 
between genetic variants as well as from the interaction of 
genetic and environmental factors. The evaluation of gene-
environment interactions according to a multiplicative or 
supra-multiplicative statistical model requires very large 
sample size to ensure an adequate power. However, the popu-
lation collected in the context of the IMMEnSE consortium 
offers the possibility to build multifactorial risk scores based 
on additive models that take into account both genetic factors 
and clinical variables and evaluate their predictive power. This 
could lead to the identification of MM susceptibility models 
able to describe and better predict the risk of MM.
The identification of ‘easy-to-use’ prognostic markers. To 
establish clear and effective prognostic factors for staging, 
outcome and survival of MM patients remains one of the most 
important issues to be addressed. Genetic markers offer the 
great advantage to be easily determinable and invariant over 
time. Thus, they appear to be ideal candidates to be employed 
as fast markers in screening, prevention and diagnosis of 
diseases. Even if with the data currently available on MM 
we are still far from this goal, the translational potential of 
pharmacogenetics appears to be relevant. In the context of 
the IMMEnSE consortium, clinical parameters at diagnosis, 
response to treatments, PFS and OS will be evaluated in rela-
tion to genetic variants studied to individuate new genetic 
prognostic markers.
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